CO2018012258A2 - Compuestos de mic-1 y usos de estos - Google Patents

Compuestos de mic-1 y usos de estos

Info

Publication number
CO2018012258A2
CO2018012258A2 CONC2018/0012258A CO2018012258A CO2018012258A2 CO 2018012258 A2 CO2018012258 A2 CO 2018012258A2 CO 2018012258 A CO2018012258 A CO 2018012258A CO 2018012258 A2 CO2018012258 A2 CO 2018012258A2
Authority
CO
Colombia
Prior art keywords
compounds
mic
amino acid
extension
relates
Prior art date
Application number
CONC2018/0012258A
Other languages
English (en)
Inventor
Henning Thøgersen
Xujia Zhang
Xiang Gao
Hongtao Guan
Kristian Sass-Ørum
Lars Fogh Iversen
Per Nørgaard
Sebastian Beck Jørgensen
Kristian Tage Hansen
Yi Wang
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Publication of CO2018012258A2 publication Critical patent/CO2018012258A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/495—Transforming growth factor [TGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1841—Transforming growth factor [TGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/27—Growth hormone [GH], i.e. somatotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/642—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a cytokine, e.g. IL2, chemokine, growth factors or interferons being the inactive part of the conjugate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/1008—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/1013—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing O or S as heteroatoms, e.g. Cys, Ser
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Toxicology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Child & Adolescent Psychology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La invención se refiere a compuestos de MIC-1. Más específicamente, se refiere a compuestos que comprenden un polipéptido MIC-1 y una extensión de aminoácido en el N-terminal, en donde dicha extensión consiste en 3 a 36 residuos de aminoácidos y donde el compuesto tiene un pI calculado inferior a 6.5. Los compuestos de la invención tienen actividad de MIC-1. La invención se refiere, además, a composiciones farmacéuticas que comprenden tales compuestos y excipientes farmacéuticamente aceptables, así como también al uso médico de los compuestos.
CONC2018/0012258A 2016-05-24 2018-11-14 Compuestos de mic-1 y usos de estos CO2018012258A2 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2016083104 2016-05-24
CN2016103574 2016-10-27
PCT/EP2017/062583 WO2017202936A1 (en) 2016-05-24 2017-05-24 Mic-1 compounds and use thereof

Publications (1)

Publication Number Publication Date
CO2018012258A2 true CO2018012258A2 (es) 2018-11-30

Family

ID=59009675

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2018/0012258A CO2018012258A2 (es) 2016-05-24 2018-11-14 Compuestos de mic-1 y usos de estos

Country Status (18)

Country Link
US (3) US20190248852A1 (es)
EP (1) EP3463412A1 (es)
JP (1) JP7013390B2 (es)
KR (1) KR102433503B1 (es)
CN (1) CN109414471A (es)
AU (1) AU2017269496B2 (es)
BR (1) BR112018072034A2 (es)
CA (1) CA3025251A1 (es)
CL (1) CL2018003319A1 (es)
CO (1) CO2018012258A2 (es)
IL (1) IL262926A (es)
MA (1) MA45113A (es)
MX (1) MX2018014023A (es)
PE (1) PE20190117A1 (es)
PH (1) PH12018502465A1 (es)
SA (1) SA518400460B1 (es)
TW (1) TW201741333A (es)
WO (1) WO2017202936A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2694092B1 (en) 2011-04-08 2017-01-04 Amgen Inc. Method of treating or ameliorating metabolic disorders using growth differentiation factor 15 (gdf-15)
MA38873B1 (fr) 2013-07-31 2018-11-30 Amgen Inc Constructions contenant le facteur 15 de différentiation de croissance (gdf-15)
TWI759301B (zh) 2016-05-24 2022-04-01 美商安美基公司 聚乙二醇化卡非佐米化合物
WO2017202936A1 (en) 2016-05-24 2017-11-30 Novo Nordisk A/S Mic-1 compounds and use thereof
AU2017371382A1 (en) 2016-12-06 2019-06-13 St Vincent's Hospital Sydney Limited Treatment of obesity and eating disorders
TWI710377B (zh) * 2017-05-23 2020-11-21 丹麥商諾佛 儂迪克股份有限公司 Ｍｉｃ－１化合物及其用途
CN111954537A (zh) 2018-04-09 2020-11-17 美国安进公司 生长分化因子15融合蛋白
US20210340205A1 (en) 2018-08-10 2021-11-04 Novartis Ag Gfral extracellular domains and methods of use
EP4041281A1 (en) 2019-10-04 2022-08-17 Amgen Inc. Use of gdf15 for treating cardiometabolic syndrome and other conditions
CN115260313B (zh) 2019-12-31 2023-07-18 北京质肽生物医药科技有限公司 Glp-1和gdf15的融合蛋白以及其缀合物
EP4237438A1 (en) * 2020-10-27 2023-09-06 Beijing QL Biopharmaceutical Co., Ltd. Fusion proteins of gdf15 and use thereof

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA954983B (en) * 1994-06-17 1996-02-14 Novo Nordisk As N-terminally extended proteins expressed in yeast
AU3247699A (en) 1998-02-17 1999-09-06 Novo Nordisk A/S Lipase variant
US6926898B2 (en) 2000-04-12 2005-08-09 Human Genome Sciences, Inc. Albumin fusion proteins
CN1152942C (zh) 2000-05-30 2004-06-09 华东理工大学 含载流子传输功能团的分子扭曲型电致发光材料及其应用
US7157235B2 (en) 2002-06-17 2007-01-02 St. Vincent's Hospital Sydney Limited Methods of diagnosis, prognosis and treatment of cardiovascular disease
CN1241946C (zh) 2002-07-01 2006-02-15 美国福源集团 对多种细胞具刺激增生作用的人血清白蛋白重组融合蛋白
WO2005099746A1 (en) 2004-04-13 2005-10-27 St Vincent's Hospital Sydney Limited Method for modulating appetite
EP2194064A1 (en) 2004-05-13 2010-06-09 Eli Lilly & Company FGF-21 fusion proteins
US20090221477A1 (en) 2004-07-26 2009-09-03 Asterion Limited Linkers
EP2076527B1 (en) 2006-10-13 2014-12-10 Novo Nordisk Health Care AG Processing enzymes fused to basic protein tags
JP2010536341A (ja) 2007-08-15 2010-12-02 アムニクス， インコーポレイテッド 生物学的に活性なポリペプチドの特性を改変するための組成物および方法
KR20110117666A (ko) 2009-01-23 2011-10-27 노보 노르디스크 에이/에스 알부민 바인더 ａ-ｂ-ｃ-ｄ-ｅ-를 갖는 ｆｇｆ21 유도체 및 그것의 사용
LT2393828T (lt) * 2009-02-03 2017-01-25 Amunix Operating Inc. Prailginti rekombinantiniai polipeptidai ir juos apimančios kompozicijos
US8680050B2 (en) 2009-02-03 2014-03-25 Amunix Operating Inc. Growth hormone polypeptides fused to extended recombinant polypeptides and methods of making and using same
AU2010258898B8 (en) * 2009-06-08 2015-02-05 Amunix Operating Inc. Glucose-regulating polypeptides and methods of making and using same
WO2011123813A2 (en) 2010-04-02 2011-10-06 Amunix Operating Inc. Binding fusion proteins, binding fusion protein-drug conjugates, xten-drug conjugates and methods of making and using same
EP2694092B1 (en) 2011-04-08 2017-01-04 Amgen Inc. Method of treating or ameliorating metabolic disorders using growth differentiation factor 15 (gdf-15)
WO2013113008A1 (en) 2012-01-26 2013-08-01 Amgen Inc. Growth differentiation factor 15 (gdf-15) polypeptides
EP2830646B1 (en) * 2012-03-27 2018-03-07 NGM Biopharmaceuticals, Inc. Compositions and methods of use for treating metabolic disorders
US9161966B2 (en) 2013-01-30 2015-10-20 Ngm Biopharmaceuticals, Inc. GDF15 mutein polypeptides
JP6272907B2 (ja) 2013-01-30 2018-01-31 エヌジーエム バイオファーマシューティカルズ インコーポレイテッド 代謝障害の処置における組成物及び使用方法
MA38873B1 (fr) 2013-07-31 2018-11-30 Amgen Inc Constructions contenant le facteur 15 de différentiation de croissance (gdf-15)
AU2014308751B2 (en) 2013-08-22 2020-03-05 Acceleron Pharma, Inc. TGF-beta receptor type II variants and uses thereof
US10588980B2 (en) 2014-06-23 2020-03-17 Novartis Ag Fatty acids and their use in conjugation to biomolecules
US9272019B2 (en) 2014-06-24 2016-03-01 Novo Nordisk A/S MIC-1 fusion proteins and uses thereof
SG11201700378PA (en) 2014-07-30 2017-02-27 Ngm Biopharmaceuticals Inc Compositions and methods of use for treating metabolic disorders
WO2016069925A1 (en) * 2014-10-30 2016-05-06 Acceleron Pharma Inc. Methods and compositions using gdf15 polypeptides for increasing red blood cells
EP3701969A1 (en) 2014-10-31 2020-09-02 NGM Biopharmaceuticals, Inc. Compositions and methods of use for treating metabolic disorders
KR102427527B1 (ko) 2014-12-23 2022-08-01 노보 노르디스크 에이/에스 Fgf21 유도체 및 그것의 용도
MA41794A (fr) 2015-03-18 2018-01-23 The California Institute For Biomedical Res Agents thérapeutiques modifiés et compositions associées
AR105269A1 (es) 2015-07-06 2017-09-20 Novo Nordisk As Péptidos y derivados de péptidos de colecistoquinina (cck) y sus usos
EA201890850A1 (ru) 2015-10-02 2018-09-28 Юлиус-Максимилианс-Универзитет Вюрцбург Комбинированное лечение с использованием ингибиторов человеческого фактора роста и дифференцировки 15 (gdf-15) и блокаторов контрольных точек иммунного ответа
WO2017055612A1 (en) 2015-10-02 2017-04-06 Julius-Maximilians-Universität Würzburg Gdf-15 as a diagnostic marker to predict the clinical outcome of a treatment with immune checkpoint blockers
GB201517528D0 (en) 2015-10-02 2015-11-18 Julius Maximillians Universitãt Würzburg GDF-15 as a diagnosis marker for melanoma
EP3393494A1 (en) 2015-12-22 2018-10-31 Novartis Ag Methods of treating or ameliorating metabolic disorders using growth differentiation factor 15 (gdf-15)
US10336812B2 (en) 2016-05-10 2019-07-02 Janssen Biotech, Inc. GDF15 fusion proteins and uses thereof
WO2017202936A1 (en) 2016-05-24 2017-11-30 Novo Nordisk A/S Mic-1 compounds and use thereof
TWI710377B (zh) 2017-05-23 2020-11-21 丹麥商諾佛 儂迪克股份有限公司 Ｍｉｃ－１化合物及其用途

Also Published As

Publication number Publication date
IL262926A (en) 2018-12-31
US20230212245A1 (en) 2023-07-06
TW201741333A (zh) 2017-12-01
KR20190008290A (ko) 2019-01-23
MX2018014023A (es) 2019-04-04
MA45113A (fr) 2019-04-10
WO2017202936A1 (en) 2017-11-30
JP2019520333A (ja) 2019-07-18
PH12018502465A1 (en) 2019-04-08
AU2017269496A1 (en) 2018-11-15
PE20190117A1 (es) 2019-01-16
JP7013390B2 (ja) 2022-01-31
BR112018072034A2 (pt) 2019-02-12
US20210198331A1 (en) 2021-07-01
AU2017269496B2 (en) 2021-03-25
CA3025251A1 (en) 2017-11-30
CN109414471A (zh) 2019-03-01
US12006344B2 (en) 2024-06-11
EP3463412A1 (en) 2019-04-10
KR102433503B1 (ko) 2022-08-18
CL2018003319A1 (es) 2019-02-01
SA518400460B1 (ar) 2022-09-21
US20190248852A1 (en) 2019-08-15
RU2018141829A (ru) 2020-06-25
RU2018141829A3 (es) 2020-10-07

Similar Documents

Publication Publication Date Title
CO2018012258A2 (es) Compuestos de mic-1 y usos de estos
CO2019013768A2 (es) Compuestos de mic-1 y usos de estos
MY187047A (en) Selective pyy compounds and uses thereof
TW201613958A (en) MIC-1 fusion proteins and uses thereof
MX341324B (es) Polipeptidos.
SA521421715B1 (ar) تركيبات سيماجلوتيد ثابتة واستخداماتها
AR120721A2 (es) Péptidos y composiciones para el tratamiento de daño articular
EA201791696A1 (ru) Композиция для лечения веноокклюзионной болезни печени
DOP2017000287A (es) Analogos glp-1 lipidados resistentes a proteasa
BR112015007592A2 (pt) composições de enalapril
BR112015013675A2 (pt) composições compreendendo vortioxetina e donepezil
CL2017003201A1 (es) Variantes de il-37
CL2019001746A1 (es) Amidas aromáticas de ácido carboxílico
EA202191515A1 (ru) Фармацевтическая композиция, содержащая апиксабан
CL2021000129A1 (es) Apirasas solubilizadas, métodos y usos
EA201691792A1 (ru) Фармацевтические составы на основе вилдаглиптина
EA201791525A3 (ru) Соединения для лечения блокады ремиелинизации при заболеваниях, связанных с экспрессией белка оболочки herv-w
EA201892837A1 (ru) Физиологически сбалансированные составы для инъекций, включающие фоснетупитант
CL2019000099A1 (es) Factor vii de coagulación de larga duración y métodos para producir el mismo.
CL2017003143A1 (es) Composición multi-péptido.
EA201891848A1 (ru) Фармацевтическая композиция для применения в лечении фиброза
EA201791648A1 (ru) Комбинация гиалуроновой кислоты и макроголя и фармацевтические композиции, содержащие ее
AR111823A1 (es) Compuestos de mic-1 y sus usos
AR099750A1 (es) COMPOSICIONES PARA LA PREVENCIÓN Y/O EL TRATAMIENTO DE PATOLOGÍAS RELACIONADAS CON LA a-GLUCOSIDASA